109 results about "Endometrial Carcinomas" patented technology

The invention relates to nitrogen-atom-containing arteannuin dimers disclosed as Formula (1) and pharmaceutically acceptable salts thereof, wherein X is NR, NR(CH2)nNR or a formula disclosed in the specification; R is H or C14 alkyl group; Y and Z are respectively (CH2)m, (CH2)n(OCH2CH2)m, OC(CH2)nCO or COAr; Ar is phenyl group, naphthyl group or heterocyclic group; N is a 2-8 whole number, and mis a 1-11 whole number; and the heterocyclic group is quinary or sexenary, and contains 1-2 heteroatoms selected from N, O and S. The invention also provides a preparation method of the nitrogen-atom-containing arteannuin dimers, a pharmaceutical composition of the nitrogen-atom-containing arteannuin dimers, and application of the nitrogen-atom-containing arteannuin dimers in preparing drugs for treating cancers, especially endometrial carcinoma, oophoroma, cervical carcinoma, breast cancer, colon cancer, lung cancer, prostatic cancer, liver cancer and/or stomach cancer.

The present invention relates to a method for diagnosis of different stages of endometrial cancer in an individual. Further, the present invention relates to a method for evaluating the probability of survival for an individual suffering from endometrial carcinoma. In another aspect, the present invention relates to the stratification of therapy regimen of endometrial tumor, ovarian cancer, breast cancer, non-small lung cancer or hormone refractory prostate cancer therapy in an individual or monitoring therapeutic efficacy in an individual suffering from the same based on the expression status of STMN1 gene or protein. Moreover, the present invention relates to a kit for use in any of the above referenced methods comprising a means for determining amplifications and deletions of chromosomal regions 3q26.32 and 12p12.1, determining alterations of the gene expression profile of the genes (gene signature): upregulation of the genes PLEKHK1, ATP10B, NMU, MMP1, ATAD2, NETO2, TNNI3, PHLDA2, OVOL1 and down-regulation of the genes: NDP, KIAA1434, MME, CFH, MOXD1, SLC47A1, RBP1, PDE8B, ASRGL1, ADAMTS19, EFHD1, ABCA5, NPAS3, SCML1, TNXB, ENTPD3, AMY1A, ENPP, RASL11B, PDZK3, or the expression status of the STMN1 gene or protein, respectively. Finally, the present invention provides a method for predicting the response to taxanes in an individual suffering from a disease treated with the taxanes based on the expression status of the STMN1 gene or protein.

The present invention relates to methods for detecting, diagnosing and/or treating endometrial cancer by detecting in a biological sample from a patient the levels of one or more of the metabolites: C14.2, PC ae C38:1, 3-Hydroxybutyric acid, C18:2, PC ae C40:1, and C6 (C4:1-DC). In some embodiments, the method also includes diagnosing the patient with endometrial cancer when the one or more metabolites in the biological sample is at a different level than a statistically validated threshold for the one or more metabolites, and ultrasound indicates endometrial cancer in the patient. In further embodiments, once endometrial cancer is diagnosed, the patient is treated for the endometrial cancer.

The invention relates to an ultra-micronized megestrol acetate in which 100% of particle sizes are smaller than or equal to 10 mu m. The invention also relates to a pharmaceutical composition containing the ultra-micronized megestrol acetate, which comprises an effective quantity of ultra-micronized megestrol acetate and medically acceptable excipient, wherein the effective quantity is 80-160 mg of ultra-micronized megestrol acetate. The pharmaceutical composition can be prepared into dispersing tablets, common tablets and capsules and used for treating advanced breast cancer, advanced endometrial carcinoma, renal carcinoma, prostatic cancer and oophoroma, and can improve the appetite and the cachexia of patients with advanced tumors.

The invention discloses biomarkers for diagnosing endometrial cancer as well as a product and application thereof, and provides application of reagents for detecting biomarkers TMSB10, EIF3E and PDIA6 in a sample to be detected in preparation of the product for diagnosing and/or assisting in diagnosing endometrial cancer. Verification results show that the combination of TMSB10, EIF3E and PDIA6 has relatively good diagnosis efficiency, whether a subject suffers from the endometrial cancer or the risk of suffering from the endometrial cancer or not can be diagnosed in an early stage according to the combination of TMSB10, EIF3E and PDIA6, and good clinical application value is achieved.

The invention relates to the field of kits, in particular to an anticancer kit for ovarian cancer and endometrial cancer. The anticancer kit comprises a kit body, a kit cover and a test tube rack, wherein the kit body comprises an outer layer and an inner layer, and a hollow vacuum heat preservation layer is arranged between the outer layer and the inner layer; the kit cover is buckled on the kitbody and sealed with the kit body, a round opening is formed in the kit cover, and a sealing cover is hinged to the opening; and the test tube rack is arranged in the kit body and comprises multiple layers of trays, the multiple layers of trays are fixed through a center shaft, the bottom end of the center shaft is connected with an output shaft of a rotating motor, the rotating motor is fixed tothe bottom wall of the inner layer of the kit body, multiple through holes are formed in each layer of tray, the circle centers of the through holes in each layer of tray are located on the same circumference, the through holes in the upper layer correspond to the through holes in the lower layer one to one, the diameter of the through holes in the tray on the bottom layer is smaller than that ofa test tube, and the distance between the circle centers of the through holes and the center shaft is equal to the distance between the opening and the axis of the center shaft. The anticancer kit hasgood heat preservation performance, sealing performance and a sterilization function, and automatic operation can be achieved.

The invention discloses a detection kit for TMEM101 gene methylation in human peripheral blood circulating tumor DNA for early screening of endometrial cancer. The detection kit is applied to early screening of endometrial cancer and comprises a methylation specific primer of a TMEM101 gene target site, a hydrolysis probe which is specific to the TMEM101 gene, and a primer of a reference gene and a hydrolysis probe of the reference gene, wherein the target site of the TMEM101 gene is at least one CpG site in an upstream and downstream 2000bp interval of a transcription start site of the TMEM101 gene; the reference gene is one or more of GAPDH and beta-actin; and the kit comprises a PCR pre-amplification reaction system and a PCR amplification reaction system. According to the provided detection kit for TMEM101 gene methylation in human peripheral blood circulating tumor DNA for early screening of endometrial cancer, the technical defects that in the prior art, the process is tedious, the detection time is long, the false positive is high, and the early screening of the endometrial cancer blood cannot be traced are overcome.

The invention provides application of SMOC2 gene (SPARC related modular calcium binding2, with the Chinese name of secreting modular calcium binding protein 2; smooth muscle related protein 2) in preparation of medicine for detecting or treating endometrial cancer and ovarian cancer. A tissue chip comprising 157 endometrial cancer tissue specimens, 30 normal proliferative phase endometrium tissue specimens and 30 normal secretory phase endometrium tissue specimens is established by utilizing a tissue microarray technology, the expression conditions of SMOC2 in the specimens are detected by utilizing the immunohistochemical technique, the positive expression rate of the SMOC2 in the normal tissue of the endometrium is far lower than the positive expression rate in the endometrial cancer, and the expression intensity is positively correlated to muscular invasion depth of the endometrial cancer and tumor grading of the endometrial cancer. Therefore, the SMOC2 gene can be used for preparing the medicine for detecting or treating endometrial cancer. The medicine is reliable in experimental result and high in repeatability and has good clinical application prospect and good application values and social benefits.

The invention relates to application of chemical drugs in the field of medicine, in particular to application of glycocholic acid in preparation of antitumor drugs. The novel applicable field of glycocholic acid is provided herein; glycocholic acid is applicable to the preparation of antitumor drugs, mainly for breast cancer, ovarian cancer, endometrial carcinoma, lung cancer or their combinations; as an effective active ingredient to antitumor drugs, glycocholic acid has effective treatment quantity of 4T1 (mouse breast cancer cells) under 0.4-1.6 nmol/L, and MCF-7 (human breast cancer cells), NIH OVCAR-3 (human ovarian carcinoma cells), RL95-2 (human endometrial cancer cells), and HCC827 (human non-small cell lung cancer cells) under 16-128 mu mol/L. The application is helpful for the development of novel antitumor drugs.

The invention provides a method for treatment of primary progesterone receptor-negative (PR−) endometrial cancer comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a progesterone receptor (PR) agonist. The invention further provides a method for treatment of a primary estrogen receptor-negative (ER−) breast cancer, comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a selective estrogen receptor modulator (SERM) or a selective estrogen receptor down-regulator (SERD). Also provided are compositions related to the above methods.

The invention discloses markers, primer probes and kit for early screening and diagnosis on an endometrial carcinoma. The markers are partial methylated regions of four genes CDO1, CELF4, HAND2 and HS3ST2, and detection primers and probes are designed for these methylated regions and are all snap-ring-type structures. The kit comprises the primers and the probes. According to the markers, the primer probes and the kit, through screening and combining multiple methylated regions, the most appropriate methylated position is determined for combined diagnosis, and the sensitivity and specificity of detection on early endometrial carcinoma can be remarkably improved. The kit is particularly suitable for carrying out early screening and diagnosis on the endometrial carcinoma by taking a cervical castoff cell as a sample, detection can be achieved in case of a low DNA template concentration, the kit has the advantages of noninvasive sampling, high detection speed, higher sensitivity and specificity, and the like, the accuracy of a result can be ensured so as to assist in achieving the aims of early discovery, early diagnosis and early treatment on the endometrial carcinoma.

Methods for diagnosing or predicting the risk of developing endometrial cancer in a subject in need of such diagnosis or risk prediction are provided, comprising measuring the expression level of at least two miRNAs disclosed herein in the sample of the subject, and compared the expression level of at least two of the miRNAs in the test sample with that of the endometrial cancer-free sample. Kits for diagnosing or predicting the risk of developing endometrial cancer, containing an agent for sequencing or measuring the expression level of at least two miRNAs disclosed herein.

The invention discloses a marker for an endometrial cancer and a detection kit thereof, and belongs to the technical field of molecular detection. According to the marker for the endometrial cancer and the detection kit thereof disclosed by the invention, all endometrial cancer patient data in a TCGA database is utilized, differentially expressed lncRNAs are analyzed, and new lncRNAs capable of predicting the lifetime of endometrial cancer patients are searched by using multiple algorithms and clinical characteristics of related patients; and the marker for the endometrial cancer, namely lnc02086, lncFAM83D and lncARL6-1, is obtained, and the marker for the endometrial cancer is used for specific detection of endometrial cancer.

The invention discloses application of a gene marker combination in diagnosis of endometrial cancer. Gene markers include COL3A1 and CD24, the gene marker combination COL3A1 and CD24 can be used for diagnosis of endometrial cancer, endometrial cancer can be accurately and rapidly diagnosed with high specificity and high sensitivity, guarantee is provided for treatment as soon as possible, and the gene marker combination is suitable for large-scale popularization.

The invention discloses an application of an ER and Ki-67 expression ratio in endometrial tissues in fertility function retention treatment prognosis of endometrial cancer (EC) and atypical endometrial hyperplasia (AH). According to the invention, 53 EC patients and 68 AH patients orally take MPA or MA, then gonadotropin is combined to release a hormone agonist and/or a levoynorethindrone intrauterine sustained release system, the patients are divided into a recurrence group and a non-recurrence group according to whether recurrence occurs after complete remission, then ER, PR, P16, P53, PTEN, Ki-67 and the like are subjected to immunohistochemical analysis, and statistical analysis is carried out. Results show that the expression rate of the Ki-67 is of great significance in predicting recurrence after the EC and AH retention fertility function treatment, and the optimal critical value (3.55) of ER/Ki-67 can predict recurrence after the EC and AH retention fertility function treatment better than that of a single immunohistochemical marker. The method has an important application value.

The invention discloses application of products related to small molecular markers in diagnosis of diseases. The small molecular markers are MARCKSL1 and RPS4X, the products comprise reagents for detecting the small molecular markers, and the products can be used for auxiliary diagnosis of endometrial cancer, can be conveniently applied to clinical rapid and effective early diagnosis of endometrial cancer, and provide support for clinical doctors to timely adopt more personalized prevention and treatment schemes.

The invention discloses a gene cooperation as an endometrial cancer marker and application thereof. The gene combination is a combination of LDHA and RPS27A, and the gene combination has the advantages of high sensitivity, high accuracy and the like when being applied to diagnosis or early diagnosis of endometrial cancer. The gene combination provided by the invention provides an effective tool for diagnosis and treatment of endometrial cancer, and is beneficial to guidance of clinical treatment.

The present invention relates to a molecular marker CD71 and applications in diagnosis, staging and prognosis of endometrial carcinoma, and belongs to the field of molecular biology, wherein the molecular marker is human transferrin receptor 1 (CD71). According to the present invention, by using the anti-human transferrin receptor 1 (CD71) antibody, the results show that human transferrin receptor 1 (CD71) is not expressed or extremely little expressed in normal endometrial tissue and precancerous lesion tissue, is specifically and highly expressed in human endometrial carcinoma tissue, and is related to the staging and the prognosis of endometrial carcinoma, such that CD71 can be used in the diagnosis, the clinical staging and the prognosis of endometrial carcinoma tissue.

The invention discloses a construction method of a lipid metabolism related endometrial cancer (UCEC) prognosis model. According to the construction method, differential genes are screened out layer by layer by using transcriptome data of UCEC in a public database TCGA to construct a prognosis model of lipid metabolism related UCEC, and it is verified that the prognosis model has good predictive capacity for endometrial cancer patients. The prognosis model can be used for guiding clinical endometrial cancer molecular typing and individualized treatment strategies, and products related to endometrial cancer diagnosis, treatment and prognosis can be further developed according to the core gene in the prognosis model.